Skip to main content
. Author manuscript; available in PMC: 2010 Oct 25.
Published in final edited form as: Hepatology. 2009 May;49(5):1449–1459. doi: 10.1002/hep.22821

Table 2.

Specificity of anti-ARFP (43-141) antibody detection with our ELISA assay in subjects with no markers of viral infection (Group III) and in patients infected by HIV (Group IV) or HBV (Group V).

Patients N Anti-ARF (43-141) Negative Response: n (%) Gray Zone Anti-ARF (43-141) Positive Response: n (%)
Group III (no infection) 187 186 (99.5%) 1 (0.5%) 0 (0%)
Group IV (HIV infection) 122 120 (98.4%) 2 (1.6%) 0 (0%)
Group V (HBV infection) 93 85 (91.4%) 7 (7.5%) 1 (1.1%)